Landmark week ahead for surging economy
The biotechnology sector will be sweating on Metabolic Pharmaceuticals' imminent announcement about the phase II clinical trial of its potential blockbuster drug for obesity treatment.
The result was due last week, but reviewing extensive data from the 300-patient trial has taken longer than expected. Metabolic's share price has weakened in recent weeks.
G
Landmark week ahead for surging economyThe biotechnology sector...
Add to My Watchlist
What is My Watchlist?